| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2022: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2021: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We initially identified a 16-gene expression signature from a total of 19245 genes, which showed significant predictive power for recurrence free survival (RFS) in non B non C HCC patients [HR: 5.02 (3.12 - 8.08), p<0.0001]. Subsequently, using clinical training cohort, we developed a reduced and optimized 4 gene signature composed of DKK1, CTSL2, MAMSTR and HLA-G, which demonstrated as a robust model in predicting RFS (HR, 3.05; 95%CI, 1.81 - 5.14; P<0.0001). The performance of the gene signature was validated in two independent clinical cohorts (HR, 3.39; 95% CI: 1.98 - 5.79, P<0.0001 and HR, 3.44; 95%CI: 1.95 - 6.06, P<0.0001). Furthermore, a nomogram comprising our four gene signature, tumor size, number of tumors, AFP, and DCP was generated to predict the 2-year recurrence free survival in the training cohort, and it performed well in the two independent validation cohorts (concordance index: 0.73 and 0.71, respectively).
|
